文献速递炎症性肠病

2010至2017年丹麦、瑞典和挪威队列中炎症性肠病的治疗管理与结局

Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
PubMed 文献 · Aliment Pharmacol Ther · 2022-07-28

该多国人群队列纳入丹麦、挪威和瑞典2010至2017年诊断的42,894例溃疡性结肠炎和24,864例克罗恩病患者,从国家登记处提取手术、住院和用药数据。结果显示2年手术率稳定(UC 4-7%、CD 10-15%),丹麦住院率上升而挪威和瑞典稳定,生物制剂和免疫调节剂使用增加但住院率无明确变化。

要点

  • 2010至2017年UC的2年手术率为4-7%,CD为10-15%,随时间保持稳定。
  • 丹麦2年住院率上升(UC 20%至35%;CD 27%至32%),挪威和瑞典稳定。
  • 生物制剂2年使用率在UC和CD中均上升,但住院率无明确变化。

核心结论

  • 2010至2017年间斯堪的纳维亚炎症性肠病患者手术率保持稳定,尽管免疫调节剂和生物制剂使用增加,住院率无明确变化。

研究设计与样本

  • 多国人群队列研究,纳入丹麦、挪威和瑞典2010至2017年诊断的42,894例溃疡性结肠炎和24,864例克罗恩病患者。
  • 从国家登记处提取手术、住院和用药数据,比较不同国家和诊断年份。

主要发现

  • 2010至2017年UC的2年手术率为4-7%,CD为10-15%,随时间保持稳定。
  • 丹麦2年住院率上升(UC 20%至35%;CD 27%至32%),挪威和瑞典稳定(UC波动于33%至37%,CD波动于46%至52%)。
  • UC的2年生物制剂使用率上升(丹麦7%至16%,挪威8%至18%),CD亦上升(丹麦22%至26%,挪威21%至35%)。
  • 挪威2年免疫调节剂使用率上升(UC 14%至23%;CD 37%至45%),瑞典CD上升(41%至52%),丹麦稳定(UC 17%至21%;CD 39%至46%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the increasing use of biologics in patients with inflammatory bowel disease (IBD), real-world data about outcomes in the era of biologics remain inconclusive. AIMS: To investigate trends in surgeries, hospitalisations and medication use in patients with IBD in a multinational, population-based cohort METHODS: We included 42,894 patients with ulcerative colitis (UC) and 24,864 with Crohn's disease (CD) who were diagnosed between 2010 and 2017 in Denmark, Norway and Sweden. We extracted data about surgeries, hospitalisations and medications from national registries and compared across countries and diagnosis years. RESULTS: Between 2010 and 2017, 2-year surgery rates were 4-7% in UC and 10-15% in CD and were stable over time. Two-year hospitalisation rates increased in Denmark (UC: 20% to 35%; CD: 27% to 32%) but were stable in Norway and Sweden (fluctuating between 33% and 37% in UC, and 46% and 52% in CD). Two-year rates of biologic use increased in both UC (7% to 16% in Denmark, 8% to 18% in Norway) and CD (22% to 26% in Denmark; 21% to 35% in Norway). Two-year rates of immunomodulator use increased in Norway (from 14% to 23% in UC; 37% to 45% in CD) and Sweden (from 41% to 52% in CD), but were stable in Denmark (between 17% and 21% in UC; 39% to 46% in CD). CONCLUSION: Between 2010 and 2017, surgery rates among Scandinavian patients with IBD remained stable, with no clear changes in hospitalisation rates despite the increasing use of immunomodulators and biologics.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Zhao M, Lirhus S, Lördal M, et al. Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway. Aliment Pharmacol Ther. 2022. PMID: 35902223. doi:10.1111/apt.17145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。